Lv71
4140 积分 2022-06-29 加入
Claudin 18.2 and Other Therapeutic Biomarkers in Gastric and Gastroesophageal Junction Adenocarcinomas
7天前
已完结
Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion–Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial
16天前
已关闭
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma
16天前
已完结
Cancer burden and control in China: landscape, trends and challenges
1个月前
已完结
Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries
1个月前
已完结
CLDN18.2-Targeted Therapy in Gastrointestinal Cancers
1个月前
已完结
Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW)
1个月前
已完结
Accelerating drug development at Bristol Myers Squibb through innovation
2个月前
已完结
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
3个月前
已完结
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
3个月前
已完结
皖公网安备34019202002308
